Research & Development

Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for all four formulations of Gobivaz – Alvotech’s biosimilar to Simponi (golimumab).

AmacaThera and Pacira sign agreement for AMT-143

AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.

Naobios and TMIMS to develop new live mpox vaccine

Naobios and Tokyo Metropolitan Institute of Medical Science (TMIMS) have announced a partnership for the development of a new mpox vaccine using a live-attenuated approach.

Tempus partners with Whitehawk on oncology research

Tempus has entered into a collaboration with Whitehawk to enhance biomarker-driven research and facilitate the development of Whitehawk's oncology pipeline.

iQure, University of Padova collaborate to investigate iQ-007 mechanism

iQure has formed a research partnership with University of Padova associate professor Laura Civiero to investigate iQ-007, the company's lead programme targeting EAAT2, the transporter responsible for glutamate uptake.

AeroRx secures $21m for nebulised COPD treatment development

AeroRx Therapeutics has secured $21m in Series A financing, led by Avalon BioVentures, with participation from Alexandria Venture Investments, Correlation Ventures, and other investors.

FDA fast-tracks Alto Neuroscience’s ALTO-101 for CIAS treatment

The US Food and Drug Administration (FDA) has awarded Fast Track designation to Alto Neuroscience’s ALTO-101, a novel small molecule phosphodiesterase-4 (PDE4) inhibitor for the treatment of cognitive impairment linked to schizophrenia (CIAS).

BioLineRx partners with Hemispherian to advance brain cancer therapy

BioLineRx and Hemispherian have formed a joint venture to advance the development of GLIX1, an oral small molecule aimed at targeting DNA damage response in glioblastoma (GBM) and other types of cancer.

Argo Biopharma secures NMPA clearance for Phase II PNH trial

Argo Biopharmaceutical has received investigational new drug (IND) approval from the National Medical Products Administration (NMPA) of China for a Phase II clinical trial of BW-40202 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).